Over the past year we have released several research articles on Aicar. We wanted to take some time to review our research and bring what we have done thus far to one place for you to review.
A study prepared in October of 2013 – Aicar
AICAR, scientifically known as 5-Aminomidaloze-4-carboxamide ribonucleotide, is a peptide that has been utilized in scientific study on animal research subjects in relation to measuring glucose uptake, insulin resistance, and energy regulation. It has also been studied via animal test subject in relation to cardiac ischemic injuries.
Another study we prepared in October of 2013 titled Buy Aicar: How AICAR Works
The functionality of AICAR was pinpointed during extensive research conducted by the Salk Institute in 2008, when it conducted a battery of studies on laboratory rats. According to this particular research, it was determined that the mice that were given AICAR exhibited a significant improvement concerning endurance-type exercise. While the mechanics of this particular improvement were not isolated and specified, it was theorized that it was due to AICAR’s facility for converting fast-twitch muscle fibers to slow-twitch muscle fibers. This conversion in turn allowed for a much higher rate of energy efficiency amongst the lab rats. Additionally, the scientific tests noted that the conversion also allowed for a more efficient fat burning process amongst the animal test subjects.
A study titled Buy AICAR From A Trusted Supplier from November of 2013
If you determine that the mechanics of AICAR are beneficial for your scientific study on animal test subjects, you should make sure you are following a couple of key steps in order to maximize the accuracy of your test results. The first step you should take is to check the purity of the peptide, as working with a diluted peptide may result in slight variances of scientific data that may ultimately cause issues over time, especially if your research is spread over several years. Secondly, you should make sure that you double-check the quantity of AICAR you would be receiving, just to confirm that the amount you are receiving is sufficient for your animal test subject study. Additionally, you should ensure that you are receiving complete and accurate research materials to accompany your peptide’s purpose.
A study from December of 2013 The Functionality of AICAR
The primary benefit that has been theorized in relation to AICAR is for the protection and treatment in relation to cardiac ischemic injury. This type of ailment is caused due to a restriction of blood supply to tissues, which in turn causes insufficient amounts of oxygen and glucose that is needed to conduct proper cellular metabolism, that is, to keep the tissue found in animal test subjects alive. While ischemic conditions can manifest itself throughout the body in the form of ailments such as vasoconstriction, embolism, or thrombosis, cardiac ischemic injury is directly related to the heart muscle, also known as the myocardium. While this condition can sometimes be asymptomatic, it is often marked by chest pain brought on by angina pectoris, also known as a lack of sufficient blood flow to the brain.
A study from Janurary of 2014 titled Aica Ribonucleotide
The scientific study based on animal test subjects has led to the theory that Aica Ribonucleotide’s ability to improve the metabolic processes within a subjects’ body would lessen the restriction of blood flow to the heart muscle, creating a more consistent sense of regulation in the process. This would theoretically enable a partially reduced risk of angina pectoris from occurring and, by extension, a reduced risk of heart failure. Additional theories based on such scientific study on animal test subjects link the peptide as a potential ally in regards to treating a heart attack that was caused by a cardiac ischemic episode. The reason for this theory also ties to Aica Ribonucleotide’s ability to lessen the restriction of blood flow to the heart, as an increase in blood flow – and subsequently and increase in glucose and oxygen getting to cardiac cells – would aid in stabilizing the heart as it recovers from an ischemic episode.
A study prepared in April of 2014 titled Aica Ribonucleotide Mechanisms
In some cardiac myocytes, aica riboside can be phosphorylated into aica-ribotide, also known as ZMP. This can activate the existing AMPK within the animal’s body— without the need to change the nucleotide levels in this area. This way, ZMP is given access to the de novo synthesis pathways which are used for adenosine synthesis: it can also be used to inhibit adenosine deaminase which will cause adenosine and ATP levels to increase throughout the animal’s body.